ASH 2017 | Front-line use of ibrutinib for CLL in a real-world setting
Ibrutinib is approved for all lines of therapy in chronic lymphocytic leukemia (CLL); however, front-line ibrutinib studies have primarily enrolled older low-risk patients, which are not representative of all patients seen in the clinic. Here, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses a multicenter retrospective study he is involved with evaluating the front-line use of ibrutinib in CLL patients treated in a real-world setting, focusing on adverse events, discontinuations, outcomes and subsequent therapies. Dr Mato highlights the encouraging results and need for trials studying the best treatment strategy post-ibrutinib. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
